Levels of vascular endothelial growth factor-A165b (VEGF-A165b) are elevated in experimental glaucoma

Molecular Vision

Volumn 14, Issue , 2008, Pages 1517-1524

  Ergorul, Ceren ^a   Ray, Arjun ^a   Huang, Wei ^a   Darland, Diane ^b   Luo, Zhonghui K ^a   Grosskreutz, Cynthia L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROGOLD; SODIUM CHLORIDE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN A164; VASCULOTROPIN A165B; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENUCLEATION; GLAUCOMA; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MALE; NONHUMAN; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RETINA; RETINA GANGLION CELL; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; GLAUCOMA; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MALE; RATS; RATS, INBRED BN; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 50549086120     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Feke GT, Pasquale LR. Retinal Blood Flow Response to Posture Change in Glaucoma Patients Compared with Healthy Subjects. Ophthalmology 2008; 115:246-52.
2. Ulrich A, Ulrich C, Barth T, Ulrich WD. Detection of disturbed autoregulation of the peripapillary choroid in primary open angle glaucoma. Ophthalmic Surg Lasers 1996; 27:746-57.
3. Gugleta K, Orgul S, Hasier PW, Picornell T, Gherghel D, Flammer J. Choroidal vascular reaction to hand-grip stress in subjects with vasospasm and its relevance in glaucoma. Invest Ophthalmol Vis Sci 2003; 44:1573-80.
4. Fuchsjager-Mayrl G, Wally B, Georgopoulos M, Rainer G, Kircher K, Buehl W, Amoako-Mensah T, Eichler HG, Vass C, Schmetterer L. Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 2004; 45:834-9.
5. Okuno T, Sugiyama T, Kojima S, Nakajima M, Ikeda T. Diurnal variation in microcirculation of ocular fundus and visual field change in normal-tension glaucoma. Eye 2004; 18:697-702.
6. Evans DW, Harris A, Garrett M, Chung HS, Kagemann L. Glaucoma patients demonstrate faulty autoregulation of ocular blood flow during posture change. Br J Ophthalmol 1999; 83:809-13.
7. Galambos P, Vafiadis J, Vilchez SE, Wagenfeld L, Matthiessen ET, Richard G, Klemm M, Zeitz O. Compromised autoregulatory control of ocular hemodynamics in glaucoma patients after postural change. Ophthalmology 2006; 113:1832-6.
8. Grunwald JE, Riva CE, Stone RA, Keates EU, Petrig BL. Retinal autoregulation in open-angle glaucoma. Ophthalmology 1984; 91: 1690-4.
9. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefansson E. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002; 21:359-93.
10. Cioffi GA, Wang L. Optic nerve blood flow in glaucoma. Semin Ophthalmol 1999; 14:164-70.
11. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88:1474-80.
12. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006; 580:2879-87.
13. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41:3158-64.
14. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000; 156:697-707.
15. Ladomery MR, Harper SJ, Bates DO. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett 2007; 249:133-42.
16. Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 2005; 6:209.
17. Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 1998; 152:1453-62.
18. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62:4123-31.
19. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L; Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO. VEGF 165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64:7822-35.
20. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 2005; 48:2422-7.
21. Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis 2006; 12:626-32.
22. Lip PL, Felmeden DC, Blann AD, Matheou N, Thakur S, Cunliffe IA, Lip GY. Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma. Br J Ophthalmol 2002; 86:1299-302.
23. Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma 2002; 11:406-10.
24. Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC. A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res 1997; 64:85-96.
25. Moore CG, Milne ST, Morrison JC. Noninvasive measurement of rat intraocular pressure with the Tono-Pen. Invest Ophthalmol Vis Sci 1993; 34:363-9.
26. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem 2004; 279:4339-45.
27. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004; 172:4618-23.
28. Kim I, Ryan AM, Rohan R, Amano S, Agular S, Miller JW, Adamis AP. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthamol Vis Sci 1999; 40:2115-21.
29. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999; 40:182-9.
30. Bates DO, MacMillan PP, Manjaly JG, Qiu Y, Hudson SJ, Bevan HS, Hunter AJ, Soothill PW, Read M, Donaldson LF, Harper SJ. The endogenous anti-angiogenic family of splice variants of VEGF, VFGFxxxb, are down-regulated in preeclamptic placentae at term. Clin Sci (Lond) 2006; 110:575-85.
31. Huez I, Bornes S, Bresson D, Creancier L, Prats H. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 2001; 15:2197-210.
32. Levy NS, Goldberg MA, Levy AP. Sequencing of the human vascular endothelial growth factor (VEGF) 3′ untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites. Biochim. Biophys Acta 1997; 1352:167-73.
33. Cui TG, Foster RR, Saleem M, Mathieson PW, Gillatt DA, Bates DO, Harper SJ. Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF 165b) mRNA and protein. Am J Physiol Renal Physiol 2004; 286:F767-73.
34. Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005; 6:386-98.
35. Stamm S. Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet 2002; 11:2409-16.
36. Hagiwara M. Alternative splicing: anew drug target of the post-genome era. Biochim Biophys Acta 2005; 1754:324-31.
37. Makeyev EV, Maniatis T. Multilevel regulation of gene expression by microRNAs. Science 2008; 319:4789-90.
38. Boutz PL, Chawla G, Stoilov P, Black DL. MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development. Genes Dev 2007; 21:71-84.
39. Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 2007; 27:435-48.
40. Komblihtt AR. Chromatin, transcript elongation and alternative splicing. Nat Struct Mol Biol 2006; 13:5-7.